e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Anti-infective treatment and resistance in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antibacterial therapy of community-acquired pneumonia (CAP) at patients with cardiovascular diseases (CVD)
H. Demchuk, Y. Mostovoy (Vinnytsia, Ukraine)
Source:
Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Session:
Anti-infective treatment and resistance in respiratory infections
Session type:
Poster Discussion
Number:
4377
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Demchuk, Y. Mostovoy (Vinnytsia, Ukraine). Antibacterial therapy of community-acquired pneumonia (CAP) at patients with cardiovascular diseases (CVD). Eur Respir J 2012; 40: Suppl. 56, 4377
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP)
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Incidence, risk factors and outcomes of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)?
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease
Source: International Congress 2019 – M-health/e-health I
Year: 2019
Cardiac diseases in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005
Prognostic factors of mortality in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 239s
Year: 2003
Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)?
Source: Eur Respir J 2003; 22: Suppl. 45, 338s
Year: 2003
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 42s
Year: 2007
Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155)
Source: International Congress 2014 – Immunology of respiratory infections
Year: 2014
Biomarkers and severity in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Impact of neutrophil function on outcomes of community-acquired pneumonia (CAP) in patients with cancer
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007
Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2012; 39: 187-196
Year: 2012
Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2011; 39: 187-196
Year: 2012
Legionella
pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in Norway
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept